Citations

Clear

4610 citation(s) found for "Lu, Brian".

NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
Jonasch, Eric, Alva, Ajjai , Bagshaw, H.P. , Costello, Brian A. , Derweesh, Ithaar , Desai, Arpita, Ged, Yasser , Johnson, Michael P. , King, Jennifer , Kyriakopoulos, Christos E. , Lara, Primo N. , Lau, Clayton, Lewis, Bryan , Mortazavi, Amir , Ponsky, Lee , Ramalingam, Sundhar, Shuch, Brian , Smith, Zachary L. , Sosman, Jeffrey A. , Zibelman, Matthew R. , Schonfeld, Ryan, Stein, MaryElizabeth , Gurski, Lisa A., Motzer, Robert J. , Agarwal, Neeraj , Baine, Michael J. , Beckermann, Kathryn E. , Carlo, Maria I. , Choueiri, Toni K. , George, Saby , Gore, John L. , Gunn, Andrew, Haas, Naomi B , Johnson, Michael, Kapur, Payal , King, Jennifer, Lam, Elaine T. , Madoff, David C. , Manley, Brandon J. , Michaelson, M. Dror , Sweis, Randy F.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 23, 2024 | Volume: 22 | Issue: 1 | Pages: 4-16

10.6004/jnccn.2024.0008 | PMID 38394781 Get It

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on the systemic therapy options for patients with advanced RCC and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Kidney Cancer.
Factors Affecting Selection of TraineE for Neurointervention (FASTEN)
Elfil, Mohamed , Ghozy, Sherief , Elmashad, Ahmed , Al‐Bayati, Alhamza R , Alaraj, Ali , Brook, Allan , Kam, Anthony W. , Waldau, Ben , Altschul, David , Parrella, David Turkel, Tóth, Gábor , Jindal, Gaurav , Shaikh, Hamza , Dolia, Jaydevsinh , Thomas, Justin, Kim, Louis J. , Harrigan, Mark R. , Kole, Max , Mokin, Max, Janjua, Nazli , Zaidat, Osama O. , Youssef, Patrick , Khandelwal, Priyank , Wang, Qingliang Tony, Szeder, Viktor , Tanweer, Omar , Jankowitz, Brian T. , Heit, Jeremy J. , Williamson, Richard , Kass‐Hout, Tareq , Crowley, R. Webster , El‐Ghanem, Mohammad , Kam, Anthony , Ghozy, Sherief , Siddiqui, Adnan H , Al-Bayati, Alhamza , Alaraj, Ali , Kam, Anthony W , Matouk, Charles , Schirmer, Clemens M , Altschul, David J , Shaikh, Hamza A , Amuluru, Krishna , Grandhi, Ramesh , Hanel, Ricardo A , Ortega-Gutierrez, Santiago , Nguyen, Thanh N , Szeder, Viktor , Heit, Jeremy J , Al-Mufti, Fawaz , Elfil, Mohamed , Dolia, Jaidevsinh , Morsi, Rami Z. , Siddiqui, Adnan H. , Chatterjee, Arindam R , Patsalides, Athos T , Prestigiacomo, Charles Joseph , Matouk, Charles , Schirmer, Clemens M. , Fifi, Johanna T , Fraser, Justin F , Kim, Louis J. , Amans, Matthew R. , Abraham, Michael G. , Jumaa, Mouhammad , Grandhi, Ramesh , Hanel, Ricardó A. , Kellogg, Ryan Thomson , Sheth, Sunil A , Nguyen, Thanh N. , Hu, Yin , Yoo, Albert J. , Al‐Mufti, Fawaz

Mayo Clinic

Interventional Neuroradiology | February 23, 2024 | Volume: 32 | Issue: 4 | Pages: 1253-1260

10.1177/15910199241232726 | PMID 38389309 Get It

Background and importance Neurointervention is a very competitive specialty in the United States due to the limited number of training spots and the larger pool of applicants. The training standards are continuously updated to ensure solid training experiences. Factors affecting candidate(s) selection have not been fully established yet. Our study aims to investigate the factors influencing the selection process. Methods A 52-question survey was distributed to 93 program directors (PDs). The survey consisted of six categories: (a) Program characteristics, (b) Candidate demographics, (c) Educational credentials, (d) Personal traits, (e) Research and extracurricular activities, and (f) Overall final set of characteristics. The response rate was 59.1%. As per the programs’ characteristics, neurosurgery was the most involved specialty in running the training programs (69%). Regarding demographics, the need for visa sponsorship held the greatest prominence with a mean score of 5.9 [standard deviation (SD) 2.9]. For the educational credentials, being a graduate from a neurosurgical residency and the institution where the candidate's residency training is/was scored the highest [5.4 (SD = 2.9), 5.4 (SD = 2.5), respectively]. Regarding the personal traits, assessment by faculty members achieved the highest score [8.9 (SD = 1)]. In terms of research/extracurricular activities, fluency in English had the highest score [7.2 (SD = 1.9)] followed by peer-reviewed/PubMed-indexed publications [6.4 (SD = 2.2)]. Conclusion Our survey investigated the factors influencing the final decision when choosing the future neurointerventional trainee, including demographic, educational, research, and extracurricular activities, which might serve as valuable guidance for both applicants and programs to refine the selection process.
Resection of Vestibular Schwannomas with CN VII Posterior to the Tumor: Surgical Techniques and Clinical Outcomes
Alexander, A. Yohan , Plitt, Aaron , Carlson, Matthew L. , Neff, Brian A., Driscoll, Colin L. W., Peris‐Celda, Maria , Link, Michael J. , Alexander, A Yohan , Carlstrom, Lucas P. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 21, 2024 | Volume: 85 | Issue: S 01 | Pages: S1-S398

10.1055/s-0044-1780093 Get It

Presenilin‐1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage
Joseph‐Mathurin, Nelly , Feldman, Rebecca L. , Lu, Ruijin , Shirzadi, Zahra , Toomer, Carmen, Clair, Junie R. Saint, Ma, Yinjiao , Strain, Jeremy F. , Kilgore, Collin , Chen, Charles D., Gordon, Brian A. , Chen, Gengsheng , Hornbeck, Russ C. , Massoumzadeh, Parinaz , Wang, Qing , Li, Yan , Wang, Guoqiao , Keefe, Sarah , Schultz, Stephanie A. , Preboske, Gregory M., Jack, Clifford R. , Ances, Beau M. , Berman, Sarah , Day, Gregory S. , Fox, Nick C. , Fulham, Michael , Ghetti, Bernardino , Johnson, Keith A. , Xiong, Chengjie , Oh, Hwamee , Perrin, Richard J. , Ringman, John M. , Saykin, Andrew J. , Supnet, Charlene , Vöglein, Jonathan , Yakushev, Igor , Morris, John C. , Chhatwal, Jasmeer P. , Network, for the Dominantly Inherited Alzheimer, Jack, Clifford R , Gordon, Brian A , Saykin, Andrew J , Day, Gregory S , Vöglein, Jonathan , Joseph-Mathurin, Nelly , Xiong, Chengjie , Chen, Charles D , Ances, Beau M , Fox, Nick C , Morris, John C , Ghetti, Bernardino F , Supnet-Bell, Charlene , Berman, Sarah , Clair, Junie Saint, McKay, Nicole S. , Friedrichsen, Karl A. , McCullough, Austin , Li, Yan, Cruchaga, Carlos , Llibre‐Guerra, Jorge J. , Allegri, Ricardo , Brooks, William S. , Cash, David M. , Jucker, Mathias , Klunk, William E. , Fougère, Christian la , Niimi, Yoshiki , Reischl, Gerald , Schofield, Peter R. , Su, Yi , Brickman, Adam M. , McDade, Eric , Xiong, Chengjie , Bateman, Randall J. , Benzinger, Tammie L.S. , Network, for the Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | February 21, 2024 | Volume: 20 | Issue: 4 | Pages: 2680-2697

10.1002/alz.13729 | PMID 38380882 Get It

AbstractINTRODUCTIONAmyloidosis, including cerebral amyloid angiopathy, and markers of small vessel disease (SVD) vary across dominantly inherited Alzheimer's disease (DIAD) presenilin‐1 (PSEN1) mutation carriers. We investigated how mutation position relative to codon 200 (pre‐/postcodon 200) influences these pathologic features and dementia at different stages.METHODSIndividuals from families with known PSEN1 mutations (n = 393) underwent neuroimaging and clinical assessments. We cross‐sectionally evaluated regional Pittsburgh compound B‐positron emission tomography uptake, magnetic resonance imaging markers of SVD (diffusion tensor imaging‐based white matter injury, white matter hyperintensity volumes, and microhemorrhages), and cognition.RESULTSPostcodon 200 carriers had lower amyloid burden in all regions but worse markers of SVD and worse Clinical Dementia Rating® scores compared to precodon 200 carriers as a function of estimated years to symptom onset. Markers of SVD partially mediated the mutation position effects on clinical measures.DISCUSSIONWe demonstrated the genotypic variability behind spatiotemporal amyloidosis, SVD, and clinical presentation in DIAD, which may inform patient prognosis and clinical trials.Highlights Mutation position influences Aβ burden, SVD, and dementia. PSEN1 pre‐200 group had stronger associations between Aβ burden and disease stage. PSEN1 post‐200 group had stronger associations between SVD markers and disease stage. PSEN1 post‐200 group had worse dementia score than pre‐200 in late disease stage. Diffusion tensor imaging‐based SVD markers mediated mutation position effects on dementia in the late stage.
Clinical Implications of Subclinical Left Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Study
Minamisawa, Masatoshi, Claggett, Brian , Čikeš, Maja , Liu, Li , Prasad, Narayana , Biering‐Sørensen, Tor , O’Meara, Eileen , Redfield, Margaret M. , Solomon, Scott D. , Shah, Amil M. , Shah, Amil , Inciardi, Riccardo M. , Lam, Carolyn S.P. , Shah, Sanjiv J , Zile, Michael R. , McMurray, John J.V. , Solomon, Scott David

Mayo Clinic

European Journal of Heart Failure | February 19, 2024 | Volume: 26 | Issue: 4 | Pages: 871-881

10.1002/ejhf.3167 | PMID 38369856 Get It

Abstract Aims Left ventricular (LV) subclinical impairment has been described in heart failure with preserved ejection fraction (HFpEF). We assessed the relationship between LV myocardial deformation by strain imaging and recurrent hospitalization for heart failure (HF) or cardiovascular death in a large international HFpEF population. Methods and results We assessed two-dimensional speckle-tracking based global longitudinal strain (GLS) in 790 patients (mean age 74 ± 8 years, 54% female) with adequate image quality enrolled in the PARAGON-HF echocardiography study. We examined the relationship of GLS with total HF hospitalizations and cardiovascular death (the primary composite outcome) after accounting for clinical confounders. Approximately 47% of the population had evidence of LV subclinical dysfunction, defined as absolute GLS <16%. Impaired GLS was significantly associated with higher values of circulating baseline N-terminal pro-B-type-natriuretic peptide. After a median follow-up of 3.0 years, there were 407 total HF hospitalizations and cardiovascular deaths. After multivariable adjustment, worse GLS was associated with a greater risk for the primary composite outcome (adjusted hazard ratio per 1% decrease: 1.06; 95% confidence interval 1.02–1.11; p = 0.008). GLS did not modify the treatment effect of sacubitril/valsartan compared with valsartan for the composite outcome (p for interaction >0.1). Conclusions In a large HFpEF population, impaired LV function was observed even among patients with preserved ejection fraction, and was associated with an increased risk of total HF hospitalizations or cardiovascular death, accounting for clinical confounders. These findings highlight the key role of subtle LV systolic impairment in the pathophysiology of HFpEF.
Deep convolutional‐neural‐network‐based metal artifact reduction for CT‐guided interventional oncology procedures (MARIO)
Cao, Wenchao , Parvinian, Ahmad , Welch, Brian T. , Callstrom, Matthew R. , Ren, Liqiang , Missert, A. , Favazza, Christopher , Adamo, Daniel, Welch, Brian, Callstrom, Matthew, Missert, Andrew, Favazza, Christopher P, Adamo, Daniel A. , Missert, Andrew

Mayo Clinic

Medical Physics | February 14, 2024 | Volume: 51 | Issue: 6 | Pages: 4231-4242

10.1002/mp.16980 | PMID 38353644 Get It

AbstractBackgroundComputed tomography (CT) is routinely used to guide cryoablation procedures. Notably, CT‐guidance provides 3D localization of cryoprobes and can be used to delineate frozen tissue during ablation. However, metal‐induced artifacts from ablation probes can make accurate probe placement challenging and degrade the ice ball conspicuity, which in combination could lead to undertreatment of potentially curable lesions.PurposeIn this work, we propose an image‐based neural network (CNN) model for metal artifact reduction for CT‐guided interventional procedures.MethodsAn image domain metal artifact simulation framework was developed and validated for deep‐learning‐based metal artifact reduction for interventional oncology (MARIO). CT scans were acquired for 19 different cryoablation probe configurations. The probe configurations varied in the number of probes and the relative orientations. A combination of intensity thresholding and masking based on maximum intensity projections (MIPs) was used to segment both the probes only and probes + artifact in each phantom image. Each of the probe and probe + artifact images were then inserted into 19 unique patient exams, in the image domain, to simulate metal artifact appearance for CT‐guided interventional oncology procedures. The resulting 361 pairs of simulated image volumes were partitioned into disjoint training and test datasets of 304 and 57 volumes, respectively. From the training partition, 116 600 image patches with a shape of 128 × 128 × 5 pixels were randomly extracted to be used for training data. The input images consisted of a superposition of the patient and probe + artifact images. The target images consisted of a superposition of the patient and probe only images. This dataset was used to optimize a U‐Net type model. The trained model was then applied to 50 independent, previously unseen CT images obtained during renal cryoablations. Three board‐certified radiologists with experience in CT‐guided ablations performed a blinded review of the MARIO images. A total of 100 images (50 original, 50 MARIO processed) were assessed across different aspects of image quality on a 4‐point likert‐type item. Statistical analyses were performed using Wilcoxon signed‐rank test for paired samples.ResultsReader scores were significantly higher for MARIO processed images compared to the original images across all metrics (all p < 0.001). The average scores of the overall image quality, iceball conspicuity, overall metal artifact, needle tip visualization, target region confidence, and worst metal artifact, needle tip visualization, iceball conspicuity, and target region confidence improved by 34.91%, 36.29%, 39.94%, 34.17%, 35.13%, and 45.70%, respectively.ConclusionsThe proposed method of image‐based metal artifact simulation can be used to train a MARIO algorithm to effectively reduce probe‐related metal artifacts in CT‐guided cryoablation procedures.
Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti–Tumor Necrosis Factor Therapy
Caldera, Freddy , Rolak, Stacey , Necela, Brian M. , Cogen, Davitte , Zona, Emily E., Schell, Trevor , Ramirez, Oscar Ramirez , Almasry, Mazen, Chun, Kelly , Knutson, Keith L. , Caldera, Freddy , Schell, Trevor L , Ramirez Ramirez, Oscar , Farraye, Francis A. , Hayney, Mary S. , Knutson, Keith L.

Mayo Clinic

Clinical and Translational Gastroenterology | February 13, 2024 | Volume: 15 | Issue: 4 | Pages: e00688

10.14309/ctg.0000000000000688 | PMID 38349178 Get It

INTRODUCTION: Studies suggest that the generation of durable T-cell immunity following coronavirus disease 2019 (COVID-19) vaccination protects against severe disease. The aim of this study was to measure cell-mediated immune response (CMIR) 1–2 months and 6 months after a third dose of a COVID-19 mRNA vaccine. METHODS: This prospective study (HumoRal and CellULar initial and Sustained immunogenicity in patients with inflammatory bowel disease [IBD]) evaluated CMIR at 28–65 days (t 1 ) after dose 2, 28–65 days (t 2 ) (n = 183) and 6 months (±45 days) (t 3 ) (n = 167) after a third dose of an mRNA COVID-19 vaccine. A small cohort had blood sample available 28–65 days (t 4 ) (n = 55) after a fourth dose. Primary outcomes were CMIR at (t 2 ) and (t 3 ). Secondary outcomes included the effect of immunosuppressing IBD medications on CMIR and response at (t 4 ). RESULTS: All patients had measurable CMIR at all time points. CMIR increased at t 2 compared with that at t 1 (median 1,467 responding cells per million (interquartile range [IQR] 410–5,971) vs 313 (94–960) P < 0.001). There was no significant waning in t 2 vs t 3 or significant boosting at t 4 . Those on anti–tumor necrosis factor monotherapy had a higher CMIR compared with those not on this therapy at t 2 (4,132 [IQR 1,136–8,795] vs 869 [IQR 343–3,221] P < 0.001) and t 3 (2,843 [IQR 596–6,459] vs 654 [IQR 143–2,067] P < 0.001). In univariable analysis, anti–tumor necrosis factor monotherapy was associated with a higher CMIR at t 2 ( P < 0.001) and t 3 ( P < 0.001) and confirmed in a multivariable model ( P < 0.001). DISCUSSION: A third dose of a COVID-19 vaccine boosts CMIR, and the response is sustained in patients with IBD.
Health AI Assurance Laboratories—Reply
Anderson, Brian, Shah, Nigam H. , Halamka, John

Mayo Clinic

JAMA | February 12, 2024 | Volume: 331 | Issue: 12 | Pages: 1062

10.1001/jama.2024.1087 | PMID 38345790 Get It

Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study
Samples, Laura , Fakhri, Bita , Khajavian, Sirin, Spurgeon, Stephen E. , Stephens, Deborah M. , Skarbnik, Alan P , Mato, Anthony R. , Broome, Catherine M. , Gopal, Ajay K. , Smith, Stephen D. , Lynch, Ryan C. , Rainey, Magdalena A., Barrett-Campbell, Odeth, Hemond, Emily, Malakhov, Nikita , Rao, Danielle, Shakib-Azar, Mehrdad, Morrigan, Beth, Chauhan, Ayushi , Plate, Thomas , Gooley, Ted, Ryan, Kellie, Hill, Brian T. , Pongas, Georgios , Allan, John N. , Cheng, Richard K. , Ujjani, Chaitra S. , Fakhri, Bita , Stephens, Deborah M , Gopal, Ajay , Smith, Stephen D , Rainey, Magdalena , Tsang, Mazie , Chauhan, Ayushi , Lansigan, Frederick , Parikh, Sameer A , Roeker, Lindsey , Allan, John N , Cheng, Richard , Ujjani, Chaitra , Voutsinas, Jenna M. , Kim, Myung Sun , Tsang, Mazie , Ermann, Daniel A. , Lansigan, Frederick , Parikh, Sameer A. , Roeker, Lindsey E. , Shadman, Mazyar

Mayo Clinic

Blood Advances | February 5, 2024 | Volume: 8 | Issue: 9 | Pages: 2085-2093

10.1182/bloodadvances.2023011569 | PMID 38315043 Get It

Abstract Although Bruton tyrosine kinase inhibitors (BTKis) are generally well tolerated and less toxic than chemotherapy alternatives used to treat lymphoid malignancies, BTKis like ibrutinib have the potential to cause new or worsening hypertension (HTN). Little is known about the optimal treatment of BTKi-associated HTN. Randomly selected patients with lymphoid malignancies on a BTKi and antihypertensive drug(s) and with at least 3 months of follow-up data were sorted into 2 groups: those diagnosed with HTN before BTKi initiation (prior-HTN), and those diagnosed with HTN after BTKi initiation (de novo HTN). Generalized estimating equations assessed associations between time varying mean arterial pressures (MAPs) and individual anti-HTN drug categories. Of 196 patients included in the study, 118 had prior-HTN, and 78 developed de novo HTN. Statistically significant mean MAP reductions were observed in patients with prior-HTN who took β blockers (BBs) with hydrochlorothiazide (HCTZ), (−5.05 mmHg; 95% confidence interval [CI], 10.0 to −0.0596; P = .047), and patients diagnosed with de novo HTN who took either an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) with HCTZ (−5.47 mmHg; 95% CI, 10.9 to −0.001; P = .05). These regimens also correlated with the greatest percentages of normotensive MAPs. Treatment of HTN in patients taking a BTKi is challenging and may require multiple antihypertensives. Patients with prior-HTN appear to benefit from combination regimens with BBs and HCTZ, whereas patients with de novo HTN appear to benefit from ACEi/ARBs with HCTZ. These results should be confirmed in prospective studies.
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis
Feagan, Brian G. , Ott, Elyssa , Gasink, Christopher , Godwin, Bridget, Marano, Colleen , Ye, Miao , Loftus, Edward V. , Sandborn, William J. , Loftus, Edward V , Danese, Silvio , Ghosh, Subrata , Ma, Tony Xuyen , Danese, Silvio , Abreu, María T. , Sands, Bruce E

Mayo Clinic

Journal of Crohn's and Colitis | February 2, 2024 | Volume: 18 | Issue: 7 | Pages: 1091-1101

10.1093/ecco-jcc/jjae013 | PMID 38310565 Get It

Abstract Background and Aims Previously published long-term safety data reported a favourable ustekinumab safety profile for the treatment of inflammatory bowel disease [IBD]. We present the final cumulative safety data from pooled ustekinumab IBD phase 2/3 clinical studies through 5 years in Crohn’s disease [CD] and 4 years in ulcerative colitis [UC]. Methods In phase 3 studies, patients received a single intravenous placebo or ustekinumab [130 mg or ~6 mg/kg] induction dose followed by subcutaneous maintenance doses of placebo or ustekinumab [90 mg q8w or q12w]. Analyses included all patients who received one dose of study treatment and included patients who were biologic-naïve and patients with a history of biologic failure. Safety outcomes are summarized and presented using number of events per 100 patient-years of follow-up and corresponding 95% confidence intervals. Results In this final pooled safety analysis, 2575 patients were treated with ustekinumab with 4826 patient-years of follow-up. Rates of key safety events, including major adverse cardiac events and malignancies, were similar between placebo and ustekinumab or not higher for ustekinumab. Opportunistic infections, including tuberculosis, and malignancies were reported infrequently. Rates of key safety events in the IBD group were no higher in the ustekinumab group than in the placebo group for both patients who were biologic-naïve or who had a history of biologic failure. No lymphomas or cases of posterior reversible encephalopathy syndrome [formerly known as reversible posterior leukoencephalopathy syndrome] were reported. Conclusion The final cumulative ustekinumab safety data through 5 years in CD and 4 years in UC demonstrated favourable safety compared to placebo and continue to support the well-established safety profile across all approved indications. Clinical trials.gov numbers NCT00265122, NCT00771667, NCT01369329, NCT01369342, NCT01369355, NCT02407236